← All trials
NCT00979745
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2009
- Primary completion
- May 1, 2011
- Completion date
- May 1, 2011
- First posted
- —
- Last posted
- —
- Enrollment
- 70
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Clinuvel Pharmaceuticals LimitedLead sponsor
- St Woolos Hospital, NewportOverall official - principal investigator
- Centre Francais des Porphyries, Hopital Louis Mourier, Colombes, FranceOverall official - principal investigator
- University of HelsinkiOverall official - principal investigator
- University of ManchesterOverall official - principal investigator
- Maastricht UniversityOverall official - principal investigator
- Erasmus University RotterdamOverall official - principal investigator
- Royal College of Surgeons, IrelandOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.